Abstract
Purpose
This study aims to evaluate the efficacy of hysteroscopic curettage combined with progestin therapy in young patients with early-stage endometrial cancer (EC) and endometrial atypical hyperplasia (EAH) who wished to preserve their fertility.
Methods
This prospective cohort study included 16 patients with early-stage EC and 25 patients with EAH in Dalian Maternal and Child Health Hospital from August 2014 to October 2018. All patients received fertility-sparing therapy with hysteroscopic evaluation every 3 months until achieving complete response (CR). Demographic, clinical, and pathological data follow-up information as well as fertility outcomes was analyzed.
Results
There were 92.6% (37/41) patients who achieved CR. The mean treatment duration to CR was 7.47 ± 2.91 months. BMI ≤ 30 kg/m2 was associated with shorter treatment duration to achieve CR (P = 0.003). Among the patients who attempted to conceive, 30.3% (10/33) had successful pregnancy, and 18.2% (6/33) delivered live births. The implementation of assisted reproductive technology (ART) is closely associated with pregnancy (P = 0.001).
Conclusion
The fertility-sparing therapy, hysteroscopic curettage combined with progestin therapy, of early young EC and EAH patients is safe and effective. BMI is the main factor affecting the duration of CR. After achieving CR, ART can significantly improve the pregnancy rate of these patients.
Similar content being viewed by others
Availability of data and material
The datasets used and analyzed during the current study are included in this article.
References
Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S (2017) Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol 28:e2
Contreras N, Sabadell J, Verdaguer P, Julià C, Fernández-Montolí M (2022) Fertility-sparing approaches in atypical endometrial hyperplasia and endometrial cancer patients: current evidence and future directions. Int J Mol Sci 23:2531
Tomao F, Peccatori F, Pup LD, Franchi D, Zanagnolo V, Panici PB, Colombo N (2015) Special issues in fertility preservation for gynecologic malignancies. Crit Rev Oncol Hematol 97:206–219
Falcone F, Balbi G, Di Martino L, Grauso F, Salzillo ME, Messalli EM (2014) Surgical management of early endometrial cancer: an update and proposal of a therapeutic algorithm. Med Sci Monit 20:1298–1313
La Rosa VL, Garzon S, Gullo G, Fichera M, Sisti G, Gallo P, Riemma G, Schiattarella A (2020) Fertility preservation in women affected by gynaecological cancer: the importance of an integrated gynaecological and psychological approach. Ecancermedicalscience 14:1035
Mazzon I, Corrado G, Masciullo V, Morricone D, Ferrandina G, Scambia G (2010) Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 93:1286–1289
Lee CL, Huang KG, Chen HL, Yen CF (2008) The roles of endoscopy in endometrial cancer. Taiwan J Obstet Gynecol 47:379–383
Bese T, Demirkiran F, Guralp O, Sanioglu C, Arvas M (2009) Transtubal transport of carcinoma cells into the peritoneal cavity after saline infusion via transcervical route in patients with endometrial carcinoma. Int J Gynecol Cancer 19:682–685
Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi MP, Student V, Mariani A (2021) Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med 112:55
Guillon S, Popescu N, Phelippeau J, Koskas M (2019) A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma. Int J Gynaecol Obstet 146:277–288
Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, Xie B, Shi Y, Luo X, Zhang H, Chen X (2019) Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol 153:55–62
Wang Q, Guo Q, Gao S, Xie F, Du M, Dong J, Sui L, Xie K (2015) Fertility-conservation combined therapy with hysteroscopic resection and oral progesterone for local early stage endometrial carcinoma in young women. Int J Clin Exp Med 8:13804
Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Cohn D, Crispens MA, Dupont N, Eifel PJ, Fader AN, Fisher CM, Gaffney DK, George S, Han E, Huh WK, Lurain JR, Martin L, Mutch D, Remmenga SW, Reynolds RK, Small WJ, Teng N, Tillmanns T, Valea FA, McMillian N, Hughes M (2014) Uterine neoplasms, version 1.2014. J Natl Compr Canc Netw 12:248–280
Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T (2007) Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25:2798–2803
Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, Ramondetta L, Bodurka DC, Westin SN (2018) Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol 131:109–116
Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, Koupolovic J, Ben-Baruch G (2003) Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 102:718–725
Ota T, Yoshida M, Kimura M, Kinoshita K (2005) Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer 15:657–662
Andress J, Pasternak J, Walter C, Kommoss S, Krämer B, Hartkopf A, Brucker SY, Schönfisch B, Steinmacher S (2021) Fertility preserving management of early endometrial cancer in a patient cohort at the department of women’s health at the university of Tuebingen. Arch Gynecol Obstet 304:215–221
Cade TJ, Quinn MA, Rome RM, Neesham D (2013) Long-term outcomes after progestogen treatment for early endometrial cancer. Aust N Z J Obstet Gynaecol 53:566–570
Zhu J, Li T, Xing W, Lin H, Ou J (2018) Chronological age vs biological age: a retrospective analysis on age-specific serum anti-Mullerian hormone levels for 3280 females in reproductive center clinic. Gynecol Endocrinol 34:890–894
Okunola T, Olusegun AK, Morebise LO, Salawu A, Omitinde SO (2017) Follicle stimulating hormone and anti-Mullerian hormone among fertile and infertile women in Ile-Ife, Nigeria: is there a difference? Int J Fertil Steril 11:33–39
Bedenk J, Vrtacnik-Bokal E, Virant-Klun I (2020) The role of anti-Mullerian hormone (AMH) in ovarian disease and infertility. J Assist Reprod Genet 37:89–100
Shan B, Ren Y, Sun J, Tu X, Jiang Z, Ju X, Zang R, Wang H (2013) A prospective study of fertility-sparing treatment with megestrol acetate following hysteroscopic curettage for well-differentiated endometrioid carcinoma and atypical hyperplasia in young women. Arch Gynecol Obstet 288:1115–1123
Tock S, Jadoul P, Squifflet JL, Marbaix E, Baurain JF, Luyckx M (2018) Fertility sparing treatment in patients with early stage endometrial cancer, using a combination of surgery and GnRH agonist: a monocentric retrospective study and review of the literature. Front Med (Lausanne) 5:240
Park JY, Seong SJ, Kim TJ, Kim JW, Bae DS, Nam JH (2017) Significance of body weight change during fertility-sparing progestin therapy in young women with early endometrial cancer. Gynecol Oncol 146:39–43
Park J, Seong SJ, Kim T, Kim JW, Kim SM, Bae D, Nam J (2013) Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer. Obstet Gynecol 121:136–142
Xlxj TONG (2013) Fertility-preserving treatment and pregnancy outcomes in the early stage of endometrial carcinoma. Chin Med J (Engl) 126:2965–2971
Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C (2009) Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 116:114–118
Acknowledgements
We would like to thank Editage (www.editage.cn) for English language editing.
Funding
None.
Author information
Authors and Affiliations
Contributions
YX: project development, data collection, manuscript editing and submission; GL: data analysis; DDL: data collection or management; JYJ: data collection; RQG: design and supervise the study. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Ethical approval
All procedures performed in studies were in accordance with the ethical standards of the institutional and/or national research committee (the Dalian Municipal Maternal and Child Health Care Hospital) and with the 1964 Declaration of Helsinki and its later amendments.
Consent to participate
Informed consent was obtained from all individual participants included in the study.
Consent for publication
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xi, Y., Liu, G., Liu, D. et al. Efficacy and pregnancy outcomes of hysteroscopic surgery combined with progestin as fertility-sparing therapy in patients with early stage endometrial cancer and atypical hyperplasia. Arch Gynecol Obstet 307, 583–590 (2023). https://doi.org/10.1007/s00404-022-06626-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-022-06626-w